Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Genentech is paying $45 million upfront for rights to ADCs designed for the growing pool of patients who progress after treatment with the modality.
Nick Paul Taylor
Aug 28, 2026 4:30am
Osivax bags flu vaccine rights to pursue combination shot vision
Aug 27, 2026 10:00am
SK's $795M deal to usher Biohaven’s epilepsy therapy towards FDA
Aug 26, 2026 4:47am
Why a congressman says China is 'beating us on our ground game'
Aug 25, 2026 9:45am
Metsera duo power Sentivera to $1.5B inflammatory disease deal
Aug 25, 2026 9:24am
Mass. biotechs bring in VC dollars but see workforce shrink
Aug 25, 2026 5:00am
